Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease
Authors' conclusion
In a large, contemporary U.S. cohort, elevated Lp(a) is independently associated with long-term MACE among individuals with and without baseline ASCVD.
Study context
- Population
- Patients with Lp(a) measured at 2 medical centres in Boston, Massachusetts, 2000–2019, with or without baseline atherosclerotic cardiovascular disease (ASCVD)
- Participants
- 16,419 patients
- Exposure
- Lp percentile groups vs 1st–50th percentile
- Outcome
- Incident MACE:
- Nonfatal MI
- Nonfatal stroke
- Coronary revascularization
- CV mortality
- Follow-up
- Median 11.9 years
Methodological details2 medical centres
- 2 medical centres
Main finding
As reported in the abstract
MACE
- 71st to 90th percentile vs 1st to 50th percentile · baseline ASCVD (n = 10,181)
- adjusted HR 1.21; P < 0.001
- 91st to 100th percentile vs 1st to 50th percentile · baseline ASCVD (n = 10,181)
- adjusted HR 1.26; P < 0.001
- 91st to 100th percentile vs 1st to 50th percentile · no established ASCVD (n = 6,238)
- adjusted HR 1.93; P < 0.001
Observational data: associations, not effects.
Original publication
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. Published 5 March 2024. doi:10.
Summarised from the published abstract; every number is checked against it